Drug profile · INN
mercaptopurine
ALLMERCAP
mercaptopurine (ALLMERCAP) is a amidophosphoribosyltransferase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — mercaptopurine
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 5
- Programs
- 10
- Data quality
- 0.84
Quick answer
mercaptopurine (ALLMERCAP) is a amidophosphoribosyltransferase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Amidophosphoribosyltransferase inhibitor
Primary target: Amidophosphoribosyltransferase
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is mercaptopurine?
mercaptopurine (ALLMERCAP) is a amidophosphoribosyltransferase inhibitor. Associated with Lacuna Pharma Pty Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for mercaptopurine?
ALLMERCAP is a marketed brand name for mercaptopurine. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of mercaptopurine?
mercaptopurine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.